In today’s briefing:
- Merger Arb Mondays (14 Oct) – Haitong/GJTA, GA Pack, Henlius, Canvest, Seven & I, Arcadium Lithium
- Rebound in Int’l Demand & Benign Fuel Prices Could Support Recovery in Chinese Airlines’ Share Perf
- Quiddity Leaderboard HS Internet & IT: Dec 24 Flow Expectations and Mar 25 Expected ADDs/DELs
- Akeso Biopharma Placement – The Placing Price Is Not Cheap Despite Positive Business Progress
- Nameson Holdings (1982 HK): 17% Dividend Yield Can Be Sustained and Improved Long-Term
- Morning Views Asia: China Jinmao Holdings, Yuexiu Property
Merger Arb Mondays (14 Oct) – Haitong/GJTA, GA Pack, Henlius, Canvest, Seven & I, Arcadium Lithium
- We summarise the latest spreads and newsflow of merger arb situations we cover across Hong Kong, Australia, New Zealand, Singapore, Japan, Indonesia, Malaysia, Philippines, Thailand and Chinese ADRs.
- Highest spreads Seven & I Holdings (3382 JP), Shanghai Henlius Biotech (2696 HK), Canvest Environmental Protection Group (1381 HK), Haitong Securities Co Ltd (H) (6837 HK), Shinko Electric Industries (6967 JP).
- Lowest spreads: Dyna Mac Holdings (DMHL SP), Xingda International (1899 HK), Fuji Soft Inc (9749 JP), Trancom Co Ltd (9058 JP), Descente Ltd (8114 JP), T Gaia Corp (3738 JP).
Rebound in Int’l Demand & Benign Fuel Prices Could Support Recovery in Chinese Airlines’ Share Perf
- By many metrics, Chinese airlines’ recent performance exceeds pre-Covid levels
- Medium-Term, ongoing int’l recovery and benign fuel prices can boost margins
- We believe the airlines could recoup weak relative performance vs Trip.com
Quiddity Leaderboard HS Internet & IT: Dec 24 Flow Expectations and Mar 25 Expected ADDs/DELs
- The Hang Seng Internet & IT (HSIII) index represents the top 30 stocks related to internet and information technology businesses listed in Hong Kong (HKEX).
- In this insight, we take a look at our capping flow expectations for the December 2024 index rebal event.
- We have also presented our index change expectations for the next semiannual index review which will take place in March 2025.
Akeso Biopharma Placement – The Placing Price Is Not Cheap Despite Positive Business Progress
- HARMONi-2 results are impressive and the overall data is solid and reliable. The NMPA has approved NDA of ebronucimab and sNDA of cadonilimab. Akeso’s fundamentals have indeed undergone positive changes.
- Akeso’s current market capitalization already partially reflects the positive expectation about the future successful FDA approval of AK112. In our view, the Placing Price is not cheap.
- When the market value falls back to below RMB45 billion is a more comfortable valuation to buy Akeso, and below RMB35 billion market value provides a golden opportunity.
Nameson Holdings (1982 HK): 17% Dividend Yield Can Be Sustained and Improved Long-Term
- HK-Listed Apparel & Footwear Screener: Right Stocks Listed in the Wrong Market—Attractive Yield & Rapid Expansion Outside China—Sep 2024 helped us screen out great names.
- Nameson Holdings (1982 HK), a knitwear supplier that trades at 4.5x PE, is net cash (considering investments) and has a 17% dividend yield, is one of them.
- We find this name attractive, and the yield can be sustainable as it shifts its supply base from China to Vietnam. Hence, we initiate with a detailed write-up.
Morning Views Asia: China Jinmao Holdings, Yuexiu Property
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.